Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1

Cancer Res. 1992 Jun 1;52(11):3119-24.

Abstract

Bryostatins are an important class of protein kinase C (PKC) activators. We have investigated the effect of bryostatin 1 on the antiproliferative activity of cis-diamminedichloroplatinum(II) (CP). A 24-h pretreatment of HeLa cells with 1 nM bryostatin 1 increased cellular sensitivity to CP by 4-fold. The effect of bryostatin 1 on the IC50 of CP (concentration of drug required to inhibit cell proliferation by 50%) was concentration-dependent and biphasic; the maximum effect of bryostatin 1 was seen with 1 nM, but higher concentrations of bryostatin 1 (greater than or equal to 10 nM) produced less CP sensitization. Although bryostatin 1 and phorbol esters caused an equivalent stimulation of HeLa cell PKC in cell-free systems, bryostatin 1 was less effective than phorbol esters in sensitizing cells to CP. Additionally, higher concentrations of bryostatin 1 (greater than or equal to 10 nM) antagonized CP sensitization by phorbol esters. Bryostatin 1 was even more potent than 12-O-tetradecanoylphorbol-13-acetate in inducing PKC down-regulation, and the maximum down-regulation was achieved with 10 nM bryostatin 1. Bryostatin 1 also increased cellular sensitivity to a CP analogue, cis-dichloro(ethylenediamine)platinum(II). A 24-h pretreatment with 1 nM bryostatin 1 increased cellular cis-[3H]DEP by 60%. The concentration- and time-dependent enhancement in CP sensitivity by bryostatin 1 was related to the increase in cis-[3H]DEP level. Thus, cellular accumulation of CP may be regulated by a PKC-dependent phosphorylation event.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology*
  • Biological Transport / drug effects
  • Bryostatins
  • Cell Division / drug effects
  • Cell Line
  • Cisplatin / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Enzyme Activation
  • HeLa Cells
  • Head and Neck Neoplasms
  • Humans
  • Isoenzymes / isolation & purification
  • Isoenzymes / metabolism
  • Kinetics
  • Lactones / pharmacology*
  • Macrolides
  • Organoplatinum Compounds / metabolism
  • Phorbol 12,13-Dibutyrate / pharmacology
  • Protein Kinase C / isolation & purification
  • Protein Kinase C / metabolism
  • Tetradecanoylphorbol Acetate / pharmacology
  • Time Factors

Substances

  • Antineoplastic Agents
  • Bryostatins
  • Isoenzymes
  • Lactones
  • Macrolides
  • Organoplatinum Compounds
  • platinum ethylenediamine dichloride
  • Phorbol 12,13-Dibutyrate
  • bryostatin 1
  • Protein Kinase C
  • Tetradecanoylphorbol Acetate
  • Cisplatin